Advertisement

Vaccine Technologies: Looking to the Future

  • F. Dorner
  • P. N. Barrett
Conference paper

Abstract

Most vaccines are designed as a prophylactic measure, that is, to stimulate the immune response so that on subsequent exposure of the vaccinated individual to the infectious agent involved, the extent of infection is so low that disease does not occur. There is also increasing interest in designing vaccines that may be effective as a therapeutic measure.

Keywords

Pertussis Vaccine Japanese Encephalitis Measle Vaccine Japanese Encephalitis Virus Polio Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ada GL (1990) The immune response to antigens: the immunological principles of vaccination. Lancet 335:523–526PubMedCrossRefGoogle Scholar
  2. Ada GL (1993) Vaccines. In: Paul WE (ed) Fundamental immunology, 3rd edn. Raven, New York, pp 1309–1352Google Scholar
  3. Ada GL (1994) Twenty years into the saga of MHC restriction. Immunol Cell Biol 72:447–454PubMedCrossRefGoogle Scholar
  4. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235–237PubMedCrossRefGoogle Scholar
  5. Cadoz M, Strady A, Meigner B, Taylor J, Tartaglia J, Paoletti E, Plotkin S (1992) Immunization with canarypox virus expressing rabies glycoprotein. Lancet 339:1429–1432PubMedCrossRefGoogle Scholar
  6. Cooper PD (1994) The selective induction of different immune responses by vaccine adjuvants. In: Ada GL (ed) Strategies in vaccine design. Landes, Austin, pp 129–158Google Scholar
  7. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1940PubMedCrossRefGoogle Scholar
  8. Fenner F (1984) Viral vectors for vaccines. In: Bell R, Torrigiani G (eds) New approaches for vaccine development. Schwabe, Basel, pp 187–192Google Scholar
  9. Gautam AM, Glynn P (1990) Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T-cells. J Immunol 144:1177–1180PubMedGoogle Scholar
  10. Geisow MJ (1991) Unravelling the mysteries of molecular audit: MHC class I restriction. Tibtech 9:403–40Google Scholar
  11. Griffin DE, Levine B, Tyor WB, Irani DN (1992) The immune response in viral encephalitis. Semin Immunol 4:111–119PubMedGoogle Scholar
  12. Halsey NA (1993) Increased mortality following high titer measles vaccines: too much of a good thing. Pediatr Infect Dis 12:462–465CrossRefGoogle Scholar
  13. Jackson DC, Ada GL, Tha Lha R (1976) Cytotoxic T cells recognize very early, minor changes in ectromelia virus-infected target cells. Aust J Exp Biol Med Sei 54:349–363CrossRefGoogle Scholar
  14. Kapikian AZ, Mitchell RH, Chanock RM (1969) An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with inactivated RS virus vaccine. Am J Epidemiol 89:405–421PubMedGoogle Scholar
  15. Kaumaya PTP, Berndt KD, Heidorn DB, Trewhella J, Kezdy FJ, Goldberg E (1990) Synthesis and biochemical characterization of engineered topographic immunogenic determinants with topology. Biochemistry 29:13–23PubMedCrossRefGoogle Scholar
  16. Larson HS, Russell RG, Rouse BY (1983) Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immunol 41:197–204Google Scholar
  17. Leung KN, Ada GL (1982) Different functions of subsets of effector T-cells in murine influenza virus infection. Cell Immunol 67:312–324PubMedCrossRefGoogle Scholar
  18. Levine MM (1994) Typhoid fever vaccines. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 597–634Google Scholar
  19. Maassab HF, Shaw MW, Heilman CA (1994) Live influenza virus vaccine. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 781–801Google Scholar
  20. Mortimer EA (1994) Pertussis vaccine. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 91–136Google Scholar
  21. Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, Hunsakunachai S, Manmontri A, Good MF (1994) Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344:639–642PubMedCrossRefGoogle Scholar
  22. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Mattaei KI, Koehler G, Kopf M (1994) The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561–563PubMedCrossRefGoogle Scholar
  23. Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev 127:157–182PubMedCrossRefGoogle Scholar
  24. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA (1996) Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lym- phocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 70:7103–7107PubMedGoogle Scholar
  25. Tartaglia J, Perkus ME, Taylor J (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232PubMedCrossRefGoogle Scholar
  26. Taylor G (1994) The role of antibody in controlling and/or clearing virus infections. In: Ada GL (ed) Strategies in vaccine design. Landes, Austin, pp 17–34Google Scholar
  27. Zinkernagel RM, Althage A (1977) Anti-viral protection by virus-immune cytotoxic T cells: infected target T-cells are lysed before infectious virus progeny is assembled. J Exp Med 145:644–651PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • F. Dorner
  • P. N. Barrett

There are no affiliations available

Personalised recommendations